Lipocine (LPCN) EBIT Growth (1y) (2013 - 2025)
Lipocine (LPCN) EBIT Growth (1y) (2013 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 8.32% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 19.82% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 145.20% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.14% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 269.85% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1,528.74% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -336.63% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 99.51% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -36.55% |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -27.77% |
| Jun 30, 2025 | 26.98% |
| Mar 31, 2025 | -164.86% |
| Dec 31, 2024 | 159.59% |
| Sep 30, 2024 | 62.65% |
| Jun 30, 2024 | 16.76% |
| Mar 31, 2024 | 174.28% |
| Dec 31, 2023 | -1.27% |
| Sep 30, 2023 | -142.93% |
| Jun 30, 2023 | -12.14% |
| Mar 31, 2023 | -38.54% |
| Dec 31, 2022 | -120.03% |
| Sep 30, 2022 | 17.95% |
| Jun 30, 2022 | -17.97% |
| Mar 31, 2022 | -0.55% |
| Dec 31, 2021 | 366.24% |
| Sep 30, 2021 | 19.23% |
| Jun 30, 2021 | 29.18% |
| Mar 31, 2021 | 32.25% |
| Dec 31, 2020 | -39.25% |